The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
about
Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in chinaExtrapolating Survival from Randomized Trials Using External Data: A Review of MethodsCost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.An economic evaluation of adaptive e-learning devices to promote weight loss via dietary change for people with obesity.Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalThe cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic reviewCan discrete event simulation be of use in modelling major depression?Modeling rheumatoid arthritis using different techniques - a review of model construction and results.Thoughts on health economics in rheumatoid arthritisBayesian methods for evidence synthesis in cost-effectiveness analysis.Health economic issues in rheumatoid arthritis.Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments.An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Modeling the effectiveness of initial management strategies for ductal carcinoma in situ.Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activityCost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis.Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece.Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models.Continuous time simulation and discretized models for cost-effectiveness analysis.Modeling Using Discrete Event SimulationUsing the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis
P2860
Q28484306-423A1238-22E7-4138-93CE-685C9A20860CQ33654108-B715D4F7-6D66-4934-87B7-C6B65566F1DCQ33726931-B981ED62-357E-4F99-B51C-CC1C33CEC1DBQ33962865-872E3BED-21F1-4592-89F0-D6B5BB69F86FQ34329499-A709E36D-A7CD-48C2-B385-7BF823E1C652Q34427423-7A21DDC5-35E1-4372-88F7-5220529C9C53Q34573847-2D6B5F1B-BE00-4171-9ACE-4BCE72EBBE6DQ35188042-F72E12F6-78A6-41E3-893D-895CB30D2604Q35568861-7BE43ECA-68C3-4081-A0E2-196155FB0F4AQ35851012-A002491A-8D3E-439A-A5EC-6EB80F4E5D0DQ36171777-3DE69DF0-F656-41D7-986C-285F3180DBB8Q36381197-6BC4549A-40E0-4088-B9BA-6365B0CFCD76Q36753625-94443B01-A8F7-4572-91B6-A81A61B08DFFQ36798538-3F9BC072-BA76-40C3-B3F8-DBD6D31773B9Q37044639-15BDFC53-176E-4D10-A8AC-8A21D0778508Q37150465-B334345C-5888-48DE-A8BB-FA60395D0FA7Q37180398-59CD2432-9493-4122-A172-E01B50205B8FQ37347655-2A5C4743-5E16-466E-9D41-026536335C03Q37782588-0FAF35F3-49E1-4F4D-9104-168D20C31E31Q38171360-F3A01061-88CA-4A58-9BDC-C8637C4DE128Q38185992-D802ECE4-8388-4B2C-BB5A-E42BAD033C06Q38775622-FCDBD011-67B4-4A89-9BCC-03479779A6D2Q39168790-71BFDBE9-408C-44C6-86B8-97015244356EQ41187128-C81AAD73-8A4F-4DED-B444-735A076ECE11Q41601731-0640ACB8-946B-420B-9590-6950D4D93630Q44700478-15E24774-37E3-4942-A1E1-E25764D02FCFQ47115080-9A21F17D-68D9-46A1-B164-32AA71A73DF3Q49054829-5AF519FB-24A1-4481-8EDF-3F97E825CB06Q57589510-0814E909-F675-4D9E-A205-C079D4C2A27BQ57995931-BD7890A6-051D-4966-B696-99883A14A82C
P2860
The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The use of modelling to evalua ...... actor in rheumatoid arthritis.
@ast
The use of modelling to evalua ...... actor in rheumatoid arthritis.
@en
type
label
The use of modelling to evalua ...... actor in rheumatoid arthritis.
@ast
The use of modelling to evalua ...... actor in rheumatoid arthritis.
@en
prefLabel
The use of modelling to evalua ...... actor in rheumatoid arthritis.
@ast
The use of modelling to evalua ...... actor in rheumatoid arthritis.
@en
P2093
P356
P1476
The use of modelling to evalua ...... actor in rheumatoid arthritis.
@en
P2093
P304
P356
10.3310/HTA8110
P577
2004-03-01T00:00:00Z